Targeting tumor cell metabolism with statins

Area of Science:

• Biochemistry
• Oncology
• Metabolic pathways

Background:

• The mevalonate pathway is essential for cholesterol synthesis, with HMGCR as its rate-limiting enzyme.
• Statins, inhibitors of HMGCR, are established hypercholesterolemia treatments.
• Emerging evidence suggests statins possess anticancer properties, but mechanisms are unclear.

Purpose of the Study:

• To review the evolution of statins from cholesterol-lowering drugs to potential anticancer agents.
• To explore the role of HMGCR and the mevalonate pathway in cancer's metabolic reprogramming.
• To elucidate tumor-selective mechanisms of statin-mediated antiproliferative effects.

Main Methods:

• Literature review of historical and recent studies on statins, HMGCR, and the mevalonate pathway.
• Analysis of research linking metabolic alterations to cancer hallmarks.
• Synthesis of findings on HMGCR's role in cellular transformation and cancer metabolism.

Main Results:

• Statins have transitioned from hypercholesterolemia treatment to agents with significant anticancer activity.
• HMGCR and the mevalonate pathway are increasingly recognized for their distinct roles in cancer development.
• Altered cancer metabolism, including the mevalonate pathway, is a critical area of cancer research.

Conclusions:

• HMGCR and the mevalonate pathway represent a promising target for novel cancer therapies.
• Understanding the metabolic reprogramming in cancer offers new avenues for statin-based anticancer strategies.
• Further research into HMGCR's tumor-selective functions is crucial for developing effective cancer treatments.